Association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with HIV on dolutegravir-based antiretroviral therapy: A cross-sectional study in Southwestern Uganda

Simple item page
dc.contributor.authorBagenda, Charles Nkubi
dc.contributor.authorNantongo, Carol
dc.contributor.authorSsemwanga, Elastus
dc.contributor.authorMugisa, Michael Junior
dc.contributor.authorAkoth, Jesca Wafwoyo
dc.contributor.authorNzaramba, Daniel
dc.contributor.authorKalyetsi, Rogers
dc.contributor.authorJohn, Elizabeth A.
dc.contributor.authorTumusiime, Jazira
dc.contributor.authorAinebyoona, Blendar
dc.contributor.authorOmara, Shadrach
dc.contributor.authorMwesigye, Vicent
dc.contributor.authorLumumba, Sylvia Achieng
dc.contributor.authorLubwama, Conrad
dc.contributor.authorMusinguzi, Benson
dc.contributor.authorAmpaire, Lucas
dc.contributor.authorNassali, Rose
dc.contributor.authorItabangi, Herbert
dc.contributor.authorOsuwat, Lawrence Obado
dc.contributor.authorSsenkumba, Brian
dc.contributor.authorOmolo, Ronald Ouma
dc.date.accessioned2026-03-23T17:35:35Z
dc.date.available2026-03-23T17:35:35Z
dc.date.issued2026-02-20
dc.descriptionThis study advances the United Nations Sustainable Development Goals, specifically SDG 3 (Good Health and Well-being) and SDG 9 (Industry, Innovation, and Infrastructure), by identifying non-high-density lipoprotein cholesterol as a predictor of Non-alcoholic Fatty Liver Disease among individuals living with Human Immunodeficiency Virus receiving Dolutegravir therapy. The findings support National Development Plan IV (NDP IV) by strengthening disease prevention, enhancing clinical decision-making, and informing evidence-based health interventions to improve chronic disease management and public health outcomes in Uganda.
dc.description.abstractNon-high-density lipoprotein cholesterol, an aggregate marker of atherogenic lipoproteins, has been implicated in metabolic dysfunction and may predict non-alcoholic fatty liver disease risk. Our study investigated the association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with Human Immunodeficiency Virus on dolutegravir-based antiretroviral therapy in southwestern Uganda. We conducted a secondary analysis of data obtained from a cross-sectional study of 377 adults who had been on dolutegravir-based antiretroviral therapy for ≥ 12 months at Ruhoko Health Centre IV, southwestern Uganda. Of the 377 participants, 42(11.1%; 95CI: 8.3–14.8) had non-alcoholic fatty liver disease. We observed a significant association between high non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease; second tertile (aOR = 3.08, 95% CI: 1.06–8.99, p = 0.039) and third tertile (aOR = 4.46, 95% CI: 1.25–15.88, p = 0.021). At an optimal cut-off of ≥ 113.4 with a sensitivity of 69% and specificity of 48%, non-high-density lipoprotein cholesterol had a significant discriminative ability; AUC = 0.654(95%CI:0.561–0.747) to distinguish participants with from those without non-alcoholic fatty liver disease. Therefore, High non-high-density lipoprotein cholesterol is a potential predictor for non-alcoholic fatty liver disease.
dc.description.sponsorshipMbarara University of Science and Technology, Faculty of Medicine, Office of the Dean, Faculty Research Support/Funding.
dc.identifier.citationBagenda, C. N., Nantongo, C., Ssemwanga, E., Mugisa, M. J., Akoth, J. W., Nzaramba, D., ... & Omolo, R. O. (2026). Association between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with HIV on dolutegravir-based antiretroviral therapy: A cross-sectional study in Southwestern Uganda. BMC Research Notes.
dc.identifier.issn1756-0500
dc.identifier.urihttps://dir.muni.ac.ug/handle/20.500.12260/941
dc.language.isoen
dc.publisherSpringer Nature
dc.subjectNon-alcoholic fatty liver disease
dc.subjectAtherogenic lipid
dc.subjectFatty liver index
dc.titleAssociation between non-high-density lipoprotein cholesterol and non-alcoholic fatty liver disease among people living with HIV on dolutegravir-based antiretroviral therapy: A cross-sectional study in Southwestern Uganda
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Musinguzi_2026_Article_20022026.pdf
Size:
925.61 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.17 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles